BlackRock, Inc. 13D and 13G filings for MaxCyte, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-05 5:28 pm Sale | 2024-12-31 | 13G | MaxCyte, Inc. MXCT | BlackRock Inc. BLK | 8,256,000 7.800% | -2,169,244 (-20.81%) | Filing |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | MaxCyte, Inc. MXCT | BlackRock Inc. BLK | 10,425,244 9.900% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | MaxCyte, Inc. MXCT | BlackRock Inc. BLK | 10,425,244 9.900% | 2,160,311 (+26.14%) | Filing |
| 2024-01-26 11:49 am Purchase | 2023-12-31 | 13G | MaxCyte, Inc. MXCT | BlackRock Inc. BLK | 8,264,933 8.000% | 531,720 (+6.88%) | Filing |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | MaxCyte, Inc. MXCT | BlackRock Inc. BLK | 7,733,213 7.600% | 890,253 (+13.01%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | MaxCyte, Inc. MXCT | BlackRock Inc. BLK | 6,842,960 6.800% | 6,842,960 (New Position) | Filing |